Clinical trial
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small…
NCT00049998 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00049998 |
|---|---|
| Title | Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer |
| Official title | An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 760 |
| Start date | Oct 1, 2001 |
| Primary completion | Apr 1, 2004 |
| First posted | Nov 20, 2002 |
| Last update posted | Mar 4, 2013 |
| Countries | Australia, Austria, Belgium, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary and 19 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: